The hypomagnesic rat model: dermatitis‐prone hairless rats with mild magnesium depletion fed a diet low in lipids did not develop pruritic dermatitis

Thomsen, Jens Peter Frølund; Nielsen, Peder Bo; Serup, Jørgen

doi:10.1111/j.1600-0846.2005.00098.x

Cited by 5 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRPM6 encodes transient receptor potential cation channel subfamily M member 6, a key regulator of cellular magnesium homeostasis 31,32 and relevant to pruritus. 33 From the patients' perspective, the improvement in itch after MSC infusion was a major health benefit, as noted previously in the pediatric population. 11 In contrast to pediatric studies, however, photographic documentation of wounds before and after MSCs showed highly variable responses, including no change or enlargement of individual wounds (Supplemental Fig 1).…”

Section: Discussionmentioning

confidence: 65%

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Rashidghamat

Kadiyirire

Ayis

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary blistering disorder due to a lack of type VII collagen. At present, treatment is mainly supportive.Objectives: To determine whether intravenous allogeneic bone marrowederived mesenchymal stromal/ stem cells (BM-MSCs) are safe in RDEB adults and if the cells improve wound healing and quality of life.Methods: We conducted a prospective, phase I/II, open-label study recruiting 10 RDEB adults to receive 2 intravenous infusions of BM-MSCs (on day 0 and day 14; each dose 2-4 3 10 6 cells/kg).Results: BM-MSCs were well tolerated with no serious adverse events to 12 months. Regarding efficacy, there was a transient reduction in disease activity scores (8/10 subjects) and a significant reduction in itch. One individual showed a transient increase in type VII collagen.Limitations: Open-label trial with no placebo.Conclusions: MSC infusion is safe in RDEB adults and can have clinical benefits for at least 2 months.

show abstract

Section: Discussionmentioning

confidence: 65%

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Rashidghamat

Kadiyirire

Ayis

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…In rats, insufficient dietary magnesium intake leads to low serum Mg 2+ concentration which results in the development of dermatitis and intense scratching [374]. Likewise, pruritus of uremic patients completely disappeared after normalizing the concentration of magnesium Mg 2+ in the dialysate [375].…”

Section: Mg 2+ Homeostasis In Itch -Possible Roles Of Trpm6 and Trpm7mentioning

confidence: 96%

TRP Channels and Pruritus

Tóth¹,

Bı́ró²

2013

TOPAINJ

View full text Add to dashboard Cite

Itch (pruritus) is one of the most often seen sensory phenomena in clinical practice. Recent neurophysiological findings proposed the existence of a novel pruriceptive system which includes a multitude of pruritogenic (itch-inducing) peripheral mediators, itch-selective pruriceptors, sensory afferent networks, spinal cord neurons, and certain central nervous system regions. In this review, we first introduce major features of the pruriceptive system. We then focus on defining the roles of transient receptor potential (TRP) ion channels in skin-coupled itch and provide compelling evidence that certain thermosensitive TRP channels (especially TRPV1, TRPV3, TRPV4, and TRPA1) are indeed key players in pruritus pathogenesis. Finally, we propose TRP-centered future experimental directions towards the therapeutic targeting of TRP channels in the clinical management of itch.

show abstract

“…Mg 2+ , resulting in universal dermatitis and intense scratching behavior [217], it is tempting to ask whether a signaling dysfunction in the "magnesium -controlling" members of the TRPM…”

Section: Trpm6 and Trpm7 -Itch And The Magnesium Connectionmentioning

confidence: 99%

TRP channels as novel players in the pathogenesis and therapy of itch

Bı́ró¹,

Tóth²,

Marincsák³

et al. 2007

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

Itch (pruritus) is a sensory phenomenon characterized by a (usually) negative affective component and the initiation of a special behavioral act, i.e. scratching. Older studies predominantly have interpreted itch as a type of pain. Recent neurophysiological findings, however, have provided compelling evidence that itch (although it indeed has intimate connections to pain) rather needs to be understood as a separate sensory modality. Therefore, a novel pruriceptive system has been proposed, within which itch-inducing peripheral mediators (pruritogens), itch-selective receptors (pruriceptors), sensory afferents and spinal cord neurons, and defined, itch-processing central nervous system regions display complex, layered responses to itch. In this review, we begin with a current overview on the neurophysiology of pruritus, and distinguish it from that of pain. We then focus on the functional characteristics of the large family of transient receptor potential (TRP) channels in skin-coupled sensory mechanisms, including itch and pain. In particular, we argue that - due to their expression patterns, activation mechanisms, regulatory roles, and pharmacological sensitivities - certain thermosensitive TRP channels are key players in pruritus pathogenesis. We close by proposing a novel, TRP-centered concept of pruritus pathogenesis and sketch important future experimental directions towards the therapeutic targeting of TRP channels in the clinical management of itch.

show abstract

The hypomagnesic rat model: dermatitis‐prone hairless rats with mild magnesium depletion fed a diet low in lipids did not develop pruritic dermatitis

Cited by 5 publications

References 13 publications

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa

TRP Channels and Pruritus

TRP channels as novel players in the pathogenesis and therapy of itch

Contact Info

Product

Resources

About